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Abstract
Deficiency of 21-hydroxylase is the most common form of congenital
adrenal hyperplasia (CAH-21OH). We determined by allele-specific
PCR the frequency of microconversion in the CYP21A2 gene in 50
Brazilian patients with the classical (salt wasting: SW and simple
virilizing: SV) forms and nonclassical (NC) form of CAH-21OH and
correlated genotype with phenotype. Genotypes were classified into
three mutation groups (A, B, and C) based on the amount of enzymatic
activity in in vitro studies using adrenal cells. In 94 unrelated alleles,
we diagnosed 76% of the affected alleles after screening for 7
microconversions. The most frequent point mutations observed in this
series were I172N (19%), V281L (18%), and IVS2,A/C>G,-12 (15%).
In the SW form, the most frequent mutation was IVS2,A/C>G,-12
(38%), in the SV form it was I172N (53%), and in the NC form it was
V281L (57.7%). We observed a good correlation between genotype
and phenotype. Discordance between genotype and phenotype was
found in one SV patient with a mild mutation in one of the alleles
(R356W/V281L). However, we cannot rule out the presence of an
additional mutation in these alleles. We also observed a good correla-
tion of genotype with 17α-hydroxyprogesterone, testosterone, and
androstenedione levels. The severity of external genitalia virilization
correlated with the severity of mutation. In conclusion, the frequencies
described in the present study did not differ from worldwide studies,
including the Brazilian population. The few differences observed may
reflect individual sample variations. This new Brazilian cohort study
suggests the presence of new mutations in Brazilian patients with
different forms of CAH-21OH.
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Introduction
Congenital adrenal hyperplasia (CAH) is
a monogenic autosomal recessive disorder
and the deficiency of 21-hydroxylase (21OH)
accounts for 90-95% of the cases (1). Steroid
21OH is a cytochrome P450 enzyme that
catalyzes the hydroxylation of 17α-hydroxy-
progesterone (17OHP) and progesterone
during cortisol and aldosterone biosynthesis
in the adrenal cortex, respectively (2). The
spectrum of clinical manifestations includes
a severe classical form with two phenotypic
classifications, salt wasting (SW) and simple
virilizing (SV), both with prenatal viriliza-
tion of external genitalia in the female fetus
and postnatal virilization in both sexes, and a
mild nonclassical form (NC), in which pa-
tients remain asymptomatic or develop symp-
toms during childhood or puberty (1).
The structural gene (CYP21A2) for 21OH
is located in the HLA class III region on the
short arm of chromosome 6 (6p21.3), as also
is the pseudogene (CYP21A1P). They pres-
ent 98% identity in exons and are located
adjacent to the genes for the complement
system, C4A and C4B (3,4). Because of the
high homology and tandem-repeat organiza-
tion of the CYP21A2 and C4 genes, this
region of the genome is subject to unequal
crossover events and gene conversions (5,6).
Therefore, the mutations that account for
21OH deficiency can be CYP21A2 deletions,
large gene conversion, or point mutations.
Furthermore, other rearrangements such as
duplications of either CYP21A2 + C4B or
CYP21A1P + C4B and deletion of CYP21A2P
+ C4B may also occur. Although these rear-
rangements are not responsible for the dis-
ease they determine different haplotypes
(7,8).
The frequency of CYP21A2 deletion and
large gene conversion varies from 20 to 33%
in several studies on Caucasian populations
(9,10). Deleterious mutations usually pres-
ent in CYP21A1P are transferred to CYP21A2
probably by microconversion events. Micro-
conversions are responsible for approxi-
mately two thirds of the affected alleles, and
approximately 40 point mutations have been
described (10,11). Furthermore, rare muta-
tions have recently been described occurring
only in CYP21A2 alleles (12-16). Most of
them are mutations found in only one chro-
mosome and are considered sporadic. Thir-
teen new different mutations have been iden-
tified in the Brazilian population (17-21).
There are codons considered to be hotspots,
such as W22, P30, G291, R356 and R483 (19).
In the present study we report the fre-
quency of 7 microconversions: P30L, a C to
T base change in exon 1; IVS2,A/C>G,-12,
an A/C to G base change in intron 2 causing
abnormal RNA splicing generating a stop
codon downstream; 706-713del8, an 8-bp
deletion in exon 3 that generates a stop codon
at position 130; I172N, a missense mutation
at residue 172 in exon 4; V281L, a G to C
base change in exon 7; Q318X, a base substi-
tution determining a stop codon in exon 8,
and R356W, a missense mutation in exon 8.
We used an allele-specific polymerase chain
reaction (PCR)-based approach in 50 Brazil-
ian families with the classical and NC forms
of CAH-21OH deficiency and correlated
genotype with phenotype.
Subjects and Methods
Patients
The study was approved by the Univer-
sity Hospital Ethics Committee and all fami-
lies gave informed consent to participate in
the genetic study. We studied 5 isolated cases
and 45 families including patients with CAH-
21OH, representing 94 unrelated affected
alleles. Among the 45 families, there was
only one affected subject in 42 and 2 af-
fected subjects in 3 families. Four of these
families were consanguineous. Patients were
assigned to one of the three clinical forms of
CAH-21OH, defined according to standard
criteria (10). Among the 50 patients, 18 pre-
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sented the SW form, 19 the SV form, and 13
the NC form. The SW form was character-
ized by extremely elevated concentrations of
17OHP and plasma renin activity, hyperka-
lemia, hyponatremia, and dehydration in the
first months of life. All females had ambigu-
ous genitalia, graded according to Prader
staging. The SV form was characterized by
ambiguous genitalia in females, sexual pre-
cocity in males without SW, and elevated
plasma 17OHP and plasma renin activity
levels. Height and bone age were advanced.
The NC form was considered to be present in
girls with normal external genitalia or mild
clitoral enlargement and was characterized by
precocious pubarche and stimulated 17OHP
of more than 1200 ng/dl in both sexes.
Hormone assays
Serum hormones (17OHP, androstenedi-
one and testosterone) were measured by ra-
dioimmunoassay, as previously described
(17), using specific antibodies provided by
Dr. José Gilberto Vieira (Fleury Labora-
tory). Tritiated hormones were purchased
from Amersham Biosciences (São Paulo,
SP, Brazil). Plasma samples were previously
extracted with ether before the assays. The
intra- and interassay coefficients of variation
were 3.3 and 16% for 17OHP, 5.2 and 6.8%
for androstenedione and 6.3 and 10% for
testosterone. The sensitivity of each method
was 16 ng/dl for 17OHP, 3.9 ng/dl for andro-
stenedione, and 10 ng/dl for testosterone.
Genotyping of mutations in the CYP21A2 gene
DNA samples were obtained from pe-
ripheral blood leukocytes by standard proce-
dures. Allele-specific PCR, as described by
Wilson et al. (22), was used for the deter-
mination of 7 microconversions (P30L,
IVS2,A/C>G,-12, 706-713del8, I172N,
V281L, Q318X, and R356W), as previously
described (19). Positive and negative control
DNA was used in all reactions.
Genotype categories
The patients were divided into three dif-
ferent genotype groups according to the im-
pairment of plasma 21OH activity, as de-
scribed by Speiser et al. (9). Group A in-
cluded patients who were homozygous for a
mutation that predicted 0% overall activity
(IVS2,A/C>G,-12, 706-713del8, Q318X,
R356W, gene deletion and macroconver-
sion), group B included patients who were
homozygous for I172N (2% of the enzy-
matic activity) or compound heterozygous
with mutation from group A. Group C in-
cluded mutations which preserve 10 to 20%
of 21OH enzymatic activity (V281L and
P30L) in homozygosity or in compound het-
erozygosity with mutations from group A
or B.
Statistical analysis
The association of each mutation with a
clinical form of the disease was determined.
Differences in basal levels of 17OHP, tes-
tosterone and androstenedione among the
three genotype groups were evaluated using
the Wilcoxon-Mann-Whitney test.
Results
In the 94 unrelated alleles, the most fre-
quent point mutations were I172N (19%),
V281L (18%), and IVS2,A/C>G,-12 (15%).
In the SW form, the most frequent mutation
was IVS2,A/C>G,-12 (38%), in the SV form
it was I172N (53%), and in the NC form it
was V281L (57.7%). There was a significant
association of IVS2,A/C>G,-12, I172N, and
V281L with the SW, SV, and NC forms,
respectively (P < 0.0001). A point mutation
was present in 70 alleles, 11 of which pre-
sented 2 point mutations (Table 1). Thus,
76% of all alleles presented at least one of
the 7 most frequent microconversions from
CYP21A1P to CYP21A2. Among the 27 pa-
tients who had mutations identified in both
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the three groups. Androstenedione levels
ranged from 144 to 7,225 (median 989) in
group A, 58 to 3,102 (median 408) in group
B, and 24 to 351 ng/dl (median 118) in group
C. Testosterone levels ranged from 32 to 648
(median 263) in group A, 59 to 466 (median
98) in group B, and 12 to 121 ng/dl (median
32) in group C. Androstenedione and testos-
terone levels were similar in groups A and
B, and these groups presented higher levels
compared to group C.
Discussion
We report here the frequencies of some
CYP21A2 gene mutations (P30L, IVS2,
A/C>G,-12, 706-713del8, I172N, V281L,
Q318X, and R356W), which may be intro-
duced into CYP21A2 from CYP21A1P by
microconversion events, in a new Brazilian
cohort with classical and NC forms of CAH-
21OH deficiency. We characterized affected
alleles by analysis of the families and corre-
lated genotype with phenotype. As duplica-
tion, deletion and gene macroconversion
events generated from hybrid genes cannot
be amplified using only PCR-based meth-
ods, future Southern blot analyses are re-
quired to identify these rearrangements in
every individual involved in this study.
The ethnic origin of the Brazilian popula-
tion is extremely heterogeneous. There are
not many data available on the genetic char-
acteristics of the CYP21A2 gene in this coun-
try (17-21). In the present study we detected
at least one mutation in 76% of the disease-
causing alleles. The two previous Brazilian
populations screened for the most frequent
mutations, which included gene deletion,
large gene conversion, and microconversions,
presented an affected allele at a frequency of
80% (18) and 85% (19). Therefore, the re-
sults of the present study confirm that in the
Brazilian population about 15-25% of the
remaining disease alleles were not eluci-
dated and might carry other rare or novel
mutations. Reports on the general popula-
Table 1. Genotype and clinical data of Brazilian patients with the salt wasting (SW),
simple virilizing (SV) and nonclassical (NC) forms of 21-hydroxylase deficiency.
Genotype Clinical form Age at diagnosis Prader stage of
female genitalia
Group A
Sp2/Sp2 SW 13 days *
Sp2/Sp2 SW at birth III
Sp2/Sp2 SW 25 days *
Q318X + R356W/Sp2 SW 1 month *
Sp2/Sp2 SW 12 days III
Q318X + R356W/Sp2 SW 20 days III
Sp2 + V281L/R356W SW 34 days III
Sp2/Q318X SW 7 months *
Group B
I172N/Sp2 + Q318X SV 9 years I
I172N/I172N SV 8 years *
I172N/R356W SV NA II
I172N/I172N SV at birth III
I172N/I172N SV at birth *
I172N/I172N SV at birth *
I172N + Q318X/I172N SV 2 years and 7 months *
I172N/I172N SV 4 years *
Q318X + R356W/I172N SV at birth III
I172N/Sp2 + Q318X SV 1 year and 1 month I
I172N/I172N SV 5 years and 7 months *
Group C
V281L/V281L NC at birth N
R356W/V281L NC 5 years I
V281L/V281L NC 6 years N
V281L/V281L NC 4 years and 9 months N
R356W/V281L NC 6 years N
V281L/V281L NC 6 years N
V281L/V281L NC 12 years *
R356W/V281L SV 4 years I
*: male patients; N: normal genitalia; NA: not available; Sp2: the intronic mutation
IVS2,A/C>G,-12.
alleles (Table 2), 8 presented the group A
genotype (all of them with the SW form), 11
patients presented the group B genotype (all
of them with the SV form), and 8 patients
presented the group C genotype (7 with NC
and 1 with SV). Virilization of the external
genitalia in group A was Prader III in all
female patients and varied from Prader I to
III in group B (Table 1). Basal 17OHP levels
ranged from 18,300 to 37,780 (median
32,620) in group A, 1,888 to 36,250 (median
14,440) in group B, and 308 to 8,500 ng/dl
(median 1224) in group C. There was a
significant difference in 17OHP levels among
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Table 2. Frequency of mutation in Brazilian patients with the classical (salt wasting: SW and simple virilizing:
SV) and nonclassical (NC) forms of 21-hydroxylase deficiency.
Present study Paulino et al. (19) Bachega et al. (18)
SW SV NC Total
Alleles (n) 33 32 26 91 68 228
P30L - - 1 1 ND 5
3.8% 1.1% 2.2%
Sp2 12 2 - 14 26% 47
48% 6% 14% 20%
∆8 1 - - 1 1.4% 3
3% 1.1% 1.3%
I172N - 18 - 18 20.5% 32
56% 20.4% 14%
V218L 1 1 15 17 4.5% 41
3% 3% 57.7% 18.2% 18%
Q318X 1 - - 1 12% 5
3% 1.1% 5.7%
R356W 1 3 2 6 9% 16
3% 9% 7.7% 6.5% 7%
P30L + I172N - - 1 1 ND ND
3.8% 1.1%
I172N + Q318X - 1 - 1 ND ND
3% 1.1%
I172N + V281L - - 1 1 ND ND
3.8% 1.1%
Q318X + R356X 2 1 - 3 ND ND
6% 3% 3.7%
Sp2 + Q318X - 2 - 2 ND ND
6% 2.2%
Sp2 + R356W 1 - - 1 ND ND
3% 1.1%
Sp2 + V281L 1 - - 1 ND ND
3% 1.1%
Sp2 + ∆8 1 - - 1 ND ND
3% 1.1%
Conv - - - ND 13.5% 7%
Del - - - ND 8.1% 5%
Conv: conversion; Del: deletion; ∆8: 706-713del8; ND: not determined; Sp2: the intronic mutation IVS2,
A/C>G,-12.
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tion diagnosed 77.6 to 95% of the alleles
(10,18,19,23-25). The highest frequency of
undiagnosed alleles was also found in other
Latin-American studies (24,26). More re-
cently, Billerbeck et al. (20), Bachega et al.
(21), and Lau et al. (27) have demonstrated
the presence of novel mutations in the
CYP21A2 gene in the Brazilian population.
Further studies searching for these muta-
tions described in previous Brazilian popu-
lations are required not only for the present
series, but also for other populations in order
to reveal if they are restricted to the Brazilian
ethnic background. In addition to the alleles
carrying one mutation, alleles with more
than one mutation are not rare and have been
observed by segregation analysis in family
studies (13,18,28). In the present study we
found that 15.8% of patients had alleles
carrying more than one mutation; most of
them were compound heterozygotes, and the
clinical form was correlated with the mu-
tated allele with higher enzymatic activity
(10,26,29).
In the 94 unrelated alleles studied in the
present series the most frequent mutations
were I172N, V281L, and IVS2,A/C>G,-12.
In the SW form, the most frequent mutation
was IVS2,A/C>G,-12, in the SV form it was
I172N, and in the NC form it was V281L,
showing a significant association between
these mutations and the clinical forms of the
disease. These results are similar to those
obtained in previous reports, in which the
intron 2 mutation was the most common,
with frequencies ranging from 18 to 36%,
followed by I172N mutation (10). Our study
showed the highest frequency for I172N when
compared to others. This result might reflect
differences in the proportion of SV cases in
each sample. V281L is generally associated
with the NC form of the disease (29,30) and
was found at a high frequency (57.7%) in our
sample, which also included NC patients.
An association of V281L in the same allele
with another mutation (R356W and P30L)
was also observed and was associated with
the classical form of the disease. In addition,
it is important to point out that V281L can
occur associated with duplication of
CYP21A1P, as previously reported (30), and
alleles carrying duplication of CYP21A1P
seem to be in linkage disequilibrium with the
NC form of CAH. In the 27 patients geno-
typed for both alleles, we found a high fre-
quency (59%) of homozygosity for point
mutations that has not been commonly re-
ported in the literature. It is important to
point out that some of these cases might be
hemizygous and, more unlikely, they might
present a de novo mutation. To clarify this
point it is necessary to perform Southern
blots and to sequence the entire CYP21A2
gene.
We observed a good, although not abso-
lute, correlation between genotype and phe-
notype (10,11). Twenty-seven patients had
mutations identified in both alleles. From
these patients, 8 presented the group A geno-
type (all of them with the SW form), 11
presented the group B genotype (all of them
with the SV form), and 8 presented the group
C genotype (7 with NC and 1 with SV).
Therefore, a discrepancy between genotype
and phenotype was found in only one patient
having the SV form. We cannot rule out the
possibility of presence of an additional new
mutation in these alleles or abnormalities in
the regulatory region of the gene. Because of
the discrepancy between phenotype and
genotype in some cases, a phenotype predic-
tion should be made with caution in prenatal
diagnosis based on molecular genetic analy-
sis of fetal DNA. We also observed a good
correlation of genotype with 17OHP, testos-
terone, and androstenedione levels, which re-
flects the extent of enzymatic activity impair-
ment. The degree of hyperandrogenism also
correlated with the severity of neonatal exter-
nal genitalia virilization, mainly in group A.
Despite the mixture of diverse ethnic ori-
gins in the Brazilian population, the muta-
tion frequencies described in the present
study did not differ from previous world-
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wide and Brazilian studies. The few differ-
ences observed may reflect subtle sample
variation in the ethnic background of the
studied population. This new Brazilian co-
hort study may suggest the presence of other
mutations in Brazilian patients with differ-
ent forms of CAH-21OH. The establishment
of genotypes in complete families with at
least one individual affected with CAH-21OH
is useful for genetic counseling, prenatal
diagnosis and prenatal treatment strategies.
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